Cardiac Manifestations in Systemic Lupus Erythematosus: A Case Report and Review of the Literature

Alexandra Kreps M.D.¹, Karen Paltoo B.A.¹ and Isabel McFarlane M.D^1,

¹Department of Medicine, Division of Rheumatology, State University of New York, Downstate Medical Center/Health + Hospitals Kings County Brooklyn, NY 11203 USA

Cite this paper:
Alexandra Kreps M.D., Karen Paltoo B.A. and Isabel McFarlane M.D. Cardiac Manifestations in Systemic Lupus Erythematosus: A Case Report and Review of the Literature. American Journal of Medical Case Reports. 2018; 6(9):180-183. doi: 10.12691/ajmcr-6-9-3

Abstract

Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with a wide range of clinical features and variable clinical course. SLE tends to affect women during childbearing years and is characterized by multi-organ involvement. Cardiac complications in SLE, which have been described to occur in about 50% of the cases, contributes to significant morbidity and mortality in this population. We describe a patient with SLE and established lupus nephritis who subsequently developed cardiac manifestations including valvular abnormalities, arrythmia and end stage heart failure. The clinical features, work up and management will be discussed. Case presentation: A 35 year-old African American woman diagnosed with SLE in her twenties presented to our hospital for evaluation of shortness of breath. After SLE diagnosis, the patient had been prescribed hydrochloroquine and low dose steroids for joint and skin manifestations. Four years after initial presentation, she developed biopsy proven lupus nephritis for which standard induction therapy was administered. She was placed on maintenance immunosuppression with stable renal function. On admission, the patient¡¯s symptoms included dyspnea on exertion, chest pain, palpitations, and a non-productive cough. Initial evaluation identified atrial fibrillation and new onset of heart failure given elevated brain natriuretic peptide (BNP) levels and left ventricular ejection fraction (EF) of 15% by echocardiogram. Cardiac catheterization revealed global hypokinesis and non-obstructive coronary artery disease (CAD). The patient was deemed not a suitable candidate for cardiac transplant and was offered a life vest as bridging to an implantable cardioverter (ICD). Twenty-four months after discharge, the patient continued to be managed medically and has not had any subsequent hospitalizations. Conclusion: Cardiac complications, reported in about 50% of SLE patients, are associated with high morbidity and mortality. Pericarditis is the most common, however conduction defects, valvular damage and heart failure are also observed among SLE patients. The pathogenesis of cardiac involvement seems to be multifactorial. The management of heart failure in SLE entails medical therapy and implantable device use. Further research is needed to explore new options to arrest the development and progression of cardiac disease among lupus patients.

Keywords:
systemic lupus erythematosus coronary heart disease coronary artery disease congestive heart failure end-stage heart failure cardioverter placement cardiac resynchronization therapy

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Jain, D., Halushka, M.K. Cardiac Pathology of Systemic Lupus Erythematosus. J Clin Pathol (2009). 62: 584-592.
[2]	Kim C.H., Al-Kindi S.G., Jandali B., Askari A.D., Zacharias M., Oliveira G.H. Incidence and risk of heart failure in systemic lupus erythematosus. Heart. 2016; 103(3): 227-233.
[3]	Jonsson, H., Nived O., Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989; 68: 141-50.
[4]	Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myo- cardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997; 145: 408-15.
[5]	Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berge R, et al.Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-7.
[6]	Posadas-Romero C, Torres-Tamayo M, Zamora-Gonzalez J, Aguilar-Herrera BE, Posadas-Sanchez R, Cardosa-Saldana G, Ladron de Guevara G, Solis-Vallejo E, El Hafidi M. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus. Arthritis Rheum. 2004; 50: 160-165.
[7]	El©\Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, et al.Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004; 110: 399-404.
[8]	Tincani, A., Rebaioli, C.B., Taglietti,M., Shoenfeld, Y., Heart Involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus, Rheumatology 2006, vol 45 (8-3).
[9]	Atalay, F., Gulmez, O., and Ugurlu, A.O. Cardiotoxicity following cyclophosphamide therapy: a case report. Journal of Medical Case Reports 2014. 8: 252.
[10]	Wu, H., Zeng, J., Yin, J., Peng, Q., Zhao, M., Lu, Q. Organ-specific biomarkers in lupus. Autoimmunity reviews. 2017. Vol 16, Issue 4. 391-397.
[11]	Leonard, D., Svenungusson, E., Sandling, J.K, et al. Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. Circ Cardiovasc Genet. 2013 Jun; 6(3): 255-63.
[12]	Ciccacci C, Perricone C, Ceccarelli F, et al. A Multilocus Genetic Study in a Cohort of Italian SLE Patients Confirms the Association with STAT4 Gene and Describes a New Association with HCP5 Gene. PLoS ONE. 2014; 9(11).
[13]	Doria A, Iaccarino L, Sarzi-Puttini P, et al. Cardiovascular involvement in systemic lupus erythemathosus, Lupus , 2005, vol. 14 (pg. 683-6).
[14]	Moyssakis I., Tektonidou M.G., Vasilliou V.A. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med. 2007; 120: 636-642.
[15]	Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman¨CSacks endocarditis) in the antiphospholipid syndrome, Circulation , 1996, vol. 93 (pg. 1579-87).
[16]	Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period: a multicenter prospective study of 1000 patients, Medicine, 1999, vol. 78 (pg. 167-75).
[17]	Ashrafi, R., Garg, P., McKay, E., Gosney, J., Chuah, S., and Davis G. Aggressive cardiac involvement in systemic lupus erythematosus: a case report and a comprehensive literature review. Cardiol Res Pract. 2011; 2011: 578390.
[18]	Raza K, Thambyrajah J, Townend JN, et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation. 2000; 102: 1470-1472.
[19]	Leonard D, Svenungsson E, Dahlqvist J, et al. Ann Rheum Dis 2018;77: 1063-1069.
[20]	EJ, Dellsperger KC. Cardiorenal Syndrome: The Clinical Cardiologists' Perspective. Cardiorenal Medicine. 2011; 1(1): 13-22.
[21]	Ridker, PM, Everett, BM, Thuren, T, MacFadyen, JG, Chang, WH, Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W, Anker, SD et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med, 377 (2017), pp. 1119-1131.